Searched over 200M research papers
2 papers analyzed
These studies suggest Diovan (valsartan) is effective in reducing mortality and cardiovascular morbidity after a myocardial infarction and in lowering arterial pressure in patients with severe arterial hypertension when used in combination with other medications.
17 papers analyzed
Diovan, also known by its generic name Valsartan, is an oral medication classified as an angiotensin II-receptor antagonist. It specifically targets the angiotensin II type 1 receptor subtype, which plays a crucial role in regulating blood pressure and cardiovascular function.
Diovan is primarily used for its antihypertensive activity, making it a valuable treatment option for patients with high blood pressure. In clinical studies, Diovan has been shown to effectively lower arterial pressure when used in combination with other antihypertensive agents such as clofelin, beta-adrenoblockers, ACE inhibitors, and diuretics. In a study involving 15 patients with severe arterial hypertension, 80% of the participants achieved satisfactory blood pressure levels with Diovan, although 13.3% did not respond to the treatment, and 6.7% experienced allergic reactions.
Diovan also plays a significant role in managing chronic heart failure (CHF) and conditions following an acute myocardial infarction (MI). The VALIANT (VALsartan In Acute myocardial iNfarcTion) trial demonstrated that Diovan is as effective as captopril, an ACE inhibitor, in reducing mortality and cardiovascular morbidity in patients who developed heart failure or left ventricular systolic dysfunction (LVSD) after surviving an MI. This makes Diovan a potential treatment option for high-risk patients in the post-MI setting.
Diovan is generally well tolerated among patients. In the VALIANT trial, it was noted that while Diovan alone was effective, combining it with captopril did not provide additional therapeutic benefits and was less well tolerated.
In the study assessing its effectiveness in severe arterial hypertension, only a small percentage of patients (13.3%) did not respond to Diovan, and 6.7% had to discontinue due to allergic reactions. Among those who completed the treatment, only two patients reported side effects, specifically headaches, within the first two weeks.
Diovan (Valsartan) is a versatile medication with proven efficacy in lowering blood pressure and managing chronic heart failure, particularly in patients who have experienced a myocardial infarction. Its ability to target the angiotensin II type 1 receptor makes it a critical option in the treatment of severe arterial hypertension and post-MI care. While generally well tolerated, it is important to monitor for potential side effects and allergic reactions during treatment.
Most relevant research papers on this topic